Sai Life Sciences LimitedQ1 FY27 Results & Financial Update
Sai Life Sciences Limited: Q1 FY27 consolidated results and company financials – revenue ₹554.29 Cr, PAT ₹73.29 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Sai Life Sciences price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Sai Life Sciences Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Sai Life Sciences reported a positive start to fiscal year 2027, with consolidated revenue from operations reaching ₹554.29 crore for the quarter ended June 30, 2026. s and the investor presentation, revenue grew by 12% year-on-year, supported by sustained commercial momentum across both its discovery (CRO) and development-manufacturing (CDMO) segments.
Profitability showed robust expansion alongside top-line growth. Consolidated profit after tax (PAT) for Q1 FY27 stood at ₹73.29 crore. In its accompanying press release and investor presentation, management highlighted a 22% year-on-year increase in net profit compared to the corresponding period of the previous fiscal year, driven by operating leverage and favorable product mix.
Earnings per share (EPS) for the quarter was reported at ₹3.42 on a basic basis and ₹3.42 on a diluted basis, reflecting the equity base following recent employee stock option allotments.
The Contract Research Organization (CRO) division maintained strong momentum during the quarter, registering a 24% year-on-year growth rate. This performance was underpinned by high client stickiness, integrated service delivery across multiple discovery platforms, and deeper collaborations with global innovator pharmaceutical firms.
The Chemistry, Manufacturing, and Control (CMC) and CDMO pipeline continued to strengthen, supported by active commercial molecules and late-phase clinical programs. Management noted that production commenced for a significant portion of molecules added to the pipeline in prior periods, and several client relationships expanded into end-to-end collaborations.
On the operational front, the company successfully operationalized a new 100,000 square foot R&D facility at its Genome Valley campus in Hyderabad, expanding its laboratory capacity. Capital expenditure remained active during the quarter, with major investments directed toward expanding R&D and manufacturing capabilities in alignment with long-term strategic targets.
Cost structures during the quarter reflected ongoing investments in scientific talent, technology platforms, and compliance infrastructure. Employee benefit expenses stood at ₹1,799.04 million, while finance costs moderated to ₹76.36 million on a consolidated basis.
Management reaffirmed confidence in executing its long-term strategy, supported by healthy balance sheet metrics, disciplined capital allocation, and strong visibility on its annual operational targets.
01 · Business model
What does Sai Life Sciences do?
Sai Life Sciences Limited is an integrated Contract Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end solutions to global innovator pharmaceutical and biotechnology companies. The company supports clients across the entire drug lifecycle, spanning early discovery, process research and development, clinical trials, and commercial manufacturing.
The company's operations are divided between two key business pillars: Contract Research Organization (CRO) services, which encompass discovery chemistry, biology, DMPK, and preclinical evaluation; and Contract Development and Manufacturing Organization (CDMO) services, focusing on complex chemistry, scale-up, and commercial API supply.
Sai Life Sciences operates world-class research and manufacturing infrastructure anchored by its integrated R&D campus in Genome Valley, Hyderabad, process R&D and discovery labs in Manchester (UK) and Boston (USA), and large-scale cGMP manufacturing facilities in Bidar, India.
The company serves a diverse global client base of over 300 active customers across the United States, United Kingdom, Europe, and Japan, including multiple top global pharmaceutical companies, underpinned by strong regulatory compliance records with agencies such as the USFDA and PMDA.
02 · Historical context
What shaped the business before this quarter
Incorporated in 1999, the company began as a medicinal chemistry partner to US biotech firms before expanding into process R&D and small-scale manufacturing.
Expanded internationally between 2019 and 2023 by establishing specialized process R&D and biology laboratories in Manchester, UK, and Greater Boston, USA.
Transitioned to a publicly listed entity through initial public offerings on the National Stock Exchange of India (NSE) and BSE Limited in December 2024.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹554.29 Cr |
| Total income | ₹557.83 Cr |
| Profit before tax | ₹97.97 Cr |
| Profit after tax | ₹73.29 Cr |
| EPS | ₹3.42 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Discovery services (CRO) grew by 24% year-on-year, driven by expanded core capabilities in chemistry, biology, DMPK, and in vivo labs.
Over 65% of discovery customers availed more than one discovery service, reflecting high client stickiness and successful cross-selling of integrated solutions.
What drove margins
Material margins expanded to ₹409 crore in Q1 FY27, representing a 15% year-on-year increase and a margin of 74% on revenue, up from 72% in Q1 FY26.
EBITDA reached ₹148 crore, marking an 18% year-on-year increase with an EBITDA margin of 27%, compared to 25% in the same quarter last year.
Cost of materials consumed and changes in inventories totaled ₹144.91 million on a consolidated basis, while employee benefit expenses reflected ongoing investments in scientific personnel.
05 · Demand, customers & order book
Where demand is coming from
The CMC pipeline features 33 active commercial molecules and 14 late-phase molecules, with average tenure of large pharma relationships exceeding 11 years.
Management reported over 90% pipeline visibility on annual FY27 targets across discovery and development operations.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The group operates in a single primary business segment of providing 'Contract Research, Development and Manufacturing Services (CRDMO)' as per Ind AS-108.
CDMO services accounted for approximately 60% of revenue mix, while CRO discovery services represented 40% during the period.
Geography and market mix
The company serves over 300 active customers across regulated markets including the US, UK, Europe, and Japan, with 19 of the top 25 global pharma companies among its clients.
Overseas laboratories in Greater Boston, USA, and Manchester, UK, continued to provide proximity to global innovation hubs and facilitate client collaborations.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Bidar manufacturing facility (Unit IV) operates 700 KL of cGMP capacity across 80 production trains and multiple specialized blocks.
Overall capacity utilization stood at 65% during the quarter, leaving adequate headroom for future volume expansion.
Projects, capex and execution
Total capex incurred during the quarter stood at ₹263 crore, supporting ongoing capacity additions at Unit IV, Bidar, and site developments.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Successfully executed commercial-scale Photo Flow Chemistry for a late-phase innovator program and commissioned a High-Throughput Experimentation (HTE) platform at Hyderabad.
Continued strategic investments in specialized modalities including Peptides, Antibody-Drug Conjugates (ADCs), Oligonucleotides, and Lipids.
09 · Reported developments
What changed operationally
Achieved the EcoVadis Platinum Rating for 2026, placing the company among the top 1% of companies globally assessed for sustainability performance.
Maintained a 100% successful track record of regulatory inspections across R&D and manufacturing facilities by agencies including the USFDA and PMDA.
10 · Management guidance & targets
What management is targeting from here
Management reiterated its confidence in sustaining long-term annual revenue growth guidance of 15% to 20% and an EBITDA margin range of 28% to 30%.
11 · Beyond the numbers
What changed beyond the numbers
Reported update
Employee Stock Option Allotment
The company allotted 506,782 equity shares of ₹1 each during the quarter consequent to the exercise of employee stock options by eligible employees under ESOP schemes.
12 · Key Q&A
The quarter, answered directly
What does Sai Life Sciences do?
Sai Life Sciences Limited is an integrated Contract Research, Development, and Manufacturing Organization (CRDMO) providing end-to-end solutions to global innovator pharmaceutical and biotechnology companies. The company supports clients across the entire drug lifecycle, spanning early discovery, process research and development, clinical trials, and commercial manufacturing.
What is the clearest takeaway from Q1 FY27?
Sai Life Sciences reported a positive start to fiscal year 2027, with consolidated revenue from operations reaching ₹554.29 crore for the quarter ended June 30, 2026. s and the investor presentation, revenue grew by 12% year-on-year, supported by sustained commercial momentum across both its discovery (CRO) and development-manufacturing (CDMO) segments.
What drove revenue or demand?
Discovery services (CRO) grew by 24% year-on-year, driven by expanded core capabilities in chemistry, biology, DMPK, and in vivo labs.
What mattered most for margins or profitability?
Material margins expanded to ₹409 crore in Q1 FY27, representing a 15% year-on-year increase and a margin of 74% on revenue, up from 72% in Q1 FY26.
What changed operationally beyond the headline numbers?
Bidar manufacturing facility (Unit IV) operates 700 KL of cGMP capacity across 80 production trains and multiple specialized blocks.
What is management guiding or targeting from here?
Management reiterated its confidence in sustaining long-term annual revenue growth guidance of 15% to 20% and an EBITDA margin range of 28% to 30%.
13 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
14 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Manufacturing Digitization: Monitor progress on the completion of the manufacturing digitization process targeted by CY 2027.
- 02
Peptide and Drug Product Facilities: Track execution milestones for the integration of the peptide platform and the addition of the Drug Product facility.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.